New drug shows promise for kids with ADHD and severe conduct issues
NCT ID NCT00626236
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested a drug called SPN-810 in 78 children aged 6 to 12 with ADHD and serious conduct problems. The main goal was to see if different doses of the drug are safe and tolerable. Researchers measured behavior changes using a special rating scale. The study was completed and in Phase 2, meaning it's still early in testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alliance Research Group
Richmond, Virginia, 23229, United States
-
CNS Healthcare
Orlando, Florida, 32806, United States
-
Capstone Clinical Research
Libertyville, Illinois, 60048, United States
-
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119, United States
-
Florida Clinical Research Center
Bradenton, Florida, 32408, United States
-
IPS Research
Oklahoma City, Oklahoma, 73103, United States
-
Northwest Clinical Trials
Bellevue, Washington, 98004, United States
-
Sarkis Clinical Trials
Gainesville, Florida, 32607, United States
-
The Psychopharm Research Cntr - LSU Dept of Psychiatry
Shreveport, Louisiana, 71103, United States
Conditions
Explore the condition pages connected to this study.